A panel of experts on nasopharyngeal carcinoma review patient cases and provide comprehensive insights on treatment practices.
EP. 1: Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach
Experts on nasopharyngeal carcinoma (NPC) provide an overview of the disease, highlighting its incidence, how it’s differentiated from other head and neck cancers, and the benefits of multidisciplinary care.
EP. 2: Current Guidelines for Managing Nasopharyngeal Carcinoma
Shravan Kandula, MD, reviews the current guidelines for the treatment of patients with nasopharyngeal carcinoma.
EP. 3: Overview of the JUPITER and POLARIS-2 Trials
Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.
EP. 4: Value of PD-L1 Biomarker in NPC
A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.
EP. 5: Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab
Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.
EP. 6: Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors
Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.
EP. 7: Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment
Victoria M. Villaflor, MD, highlights ways to mitigate adverse events for patients receiving treatment for nasopharyngeal carcinoma.
EP. 8: Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma
The panel provides clinical insights on nasopharyngeal carcinoma treatment practices and outlines unmet needs in the current therapeutic landscape.
Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC
Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC
Neoadjuvant Chemotherapy Could Enhance Organ Preservation in Nasal and Paranasal Sinus Squamous Cell Carcinoma
Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups